Hawk Research Advisors
Report Date: 19/01/2016
ConforMIS, Inc. (NASDAQ: CFMS)
· Researcher: SkyTides
· Long term Price target: $0 (December 31, 2016 at the latest)
· Short term Price targe: $2.50 (Cash level: $128 million / 47 million, rounded to nearest half dollar).
· SkyTides is short of CFMS, may add to their short position at any time.
o Two (2) CFMS product defects identified by orthopedic expert, member of 35+ market leader implant design teams, calls CFMS knee implant "something you would have seen in the 1960s"
o Under oath, CFMS affiliated surgeon says CFMS product "an unreasonably dangerous knee implant"
o FDA data: CFMS patients 32 times more likely to have an adverse event compared to market leader
o Surgeon survey reveals little love for CFMS key product, suggests product seen as a marketing gimmick
o 5 recalls in 7 years, further evidence that perception of CFMS superior technology is a myth
THIS IS JUST A SUMMARTY OF SKYTIDES REPORT ON CFMS FOR THE FULL REPORT CHECK: skytides.com/article/conformis-expert-co...